{"id":27940,"date":"2025-12-22T11:18:05","date_gmt":"2025-12-22T15:18:05","guid":{"rendered":"https:\/\/www.red94.net\/news\/pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-guidance-cut-has-investors-wondering-what-comes-next\/"},"modified":"2025-12-22T11:18:05","modified_gmt":"2025-12-22T15:18:05","slug":"90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g","status":"publish","type":"post","link":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/","title":{"rendered":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next"},"content":{"rendered":"

Pfizer stock<\/b> took a significant hit this week as the pharmaceutical giant slashed its 2026 revenue guidance<\/b>, sending shockwaves through investor portfolios. The company revealed that COVID-19 product sales<\/b> will decline dramatically, marking a turning point for the drugmaker that rode pandemic profits to record heights. Markets are now grappling with what this slowdown means for Pfizer’s ability to maintain shareholder returns in an increasingly challenging landscape.<\/p>\n

\n

\ud83d\udd25 Quick Facts<\/h3>\n
    \n
  • 2026 revenue guidance<\/b> reduced to $59.5-62.5 billion<\/b>, below analyst expectations<\/li>\n
  • COVID-19 sales<\/b> projected to fall $1.5 billion<\/b> to just $5 billion<\/b> in 2026<\/li>\n
  • Stock plunged 5%<\/b> following the December 16 guidance announcement<\/li>\n
  • Adjusted EPS outlook of $2.80-$3.00<\/b> trails consensus estimate of $3.05-$3.09<\/b><\/li>\n<\/ul>\n<\/div>\n

    The COVID Cliff Finally Hits Pfizer’s Bottom Line<\/h2>\n

    After years of blockbuster revenue from its COVID-19 vaccine and treatment portfolio<\/b>, Pfizer now confronts the inevitable decline as pandemic demand normalizes. The company previously booked massive sales from these products, positioning them as cornerstone revenue generators throughout 2024 and 2025. Now reality sets in with a projected $1.5 billion revenue drop<\/b> in the coming year.<\/p>\n

    This decline reflects broader pharmaceutical industry trends where temporary pandemic products fail to sustain their outsized contribution once emergency demand fades. Pfizer’s acknowledgment that COVID products will generate merely $5 billion<\/b> in 2026 signals management’s realistic reckoning with market conditions. The company is essentially admitting what investors feared during the pandemic boom: these revenues were cyclical, not structural.<\/p>\n

    Investor Nerves Frayed by Lower Earnings Impact<\/h2>\n

    The guidance cut hits investors on multiple fronts simultaneously. Not only is total revenue facing headwinds, but earnings per share<\/b> is also expected to compress. The company’s revised $2.80-$3.00<\/b> adjusted EPS range sits materially below what Wall Street anticipated, creating immediate portfolio pressure.<\/p>\n

    This divergence between company projections and analyst estimates matters enormously for institutional investors managing billions in pharmaceutical sector exposure. When a major pharma player signals that earnings growth will prove weaker than consensus, it raises uncomfortable questions about industry-wide profitability trends. Investors paying attention are asking whether other large drugmakers face similar headwinds waiting to be disclosed.<\/p>\n

    Financial Metrics Paint a Challenging Picture for 2026<\/h2>\n\n\n\n\n\n\n
    Financial Metric<\/td>\n2026 Guidance<\/td>\nPrevious Range<\/td>\n<\/tr>\n
    Total Revenue<\/td>\n$59.5-$62.5B<\/b><\/td>\nNot provided<\/td>\n<\/tr>\n
    COVID Product Revenue<\/td>\n$5 billion<\/b><\/td>\n$6.5 billion (2025)<\/td>\n<\/tr>\n
    Adjusted EPS<\/td>\n$2.80-$3.00<\/b><\/td>\nConsensus: $3.05-$3.09<\/td>\n<\/tr>\n
    COVID Revenue Decline YoY<\/td>\n-$1.5 billion<\/b><\/td>\n\u2014<\/td>\n<\/tr>\n<\/table>\n

    Patent Cliffs and Strategic Investments Compound the Pressure<\/h2>\n

    Beyond COVID-related headwinds, Pfizer faces additional structural challenges ahead. The company is confronting multiple patent expirations<\/b> on established products, a predictable but serious threat to revenue stability. Management is banking on strategic investments in its pipeline to offset these losses, but investors remain skeptical given the scale of the challenge.<\/p>\n

    The pharmaceutical giant has acquired companies like Seagen<\/b> to bolster its oncology portfolio, yet these acquisitions themselves create near-term dilution to earnings per share. The market is clearly questioning whether new pipeline products can generate sufficient revenue to compensate for both the COVID cliff and approaching patent expirations. These execution concerns directly contributed to the stock’s sharp 5% decline<\/b> following the announcement.<\/p>\n

    What Comes Next for Pfizer and Pharmacy Investors?<\/h2>\n

    The real question facing the market is whether this guidance adjustment represents a bottom from which recovery is possible, or merely the first of several downward revisions. Pharmaceutical sector investors<\/b> are watching closely to see if competitors face similar pressures or if Pfizer’s struggles are particularly acute. The stock’s reaction suggests investors are pricing in extended uncertainty about the company’s ability to execute its turnaround strategy.<\/p>\n

    Management must now deliver on promises that emerging therapies and strategic acquisitions will offset pandemic revenue losses. Delayed product launches, regulatory setbacks, or disappointing clinical trial results could easily trigger additional guidance cuts. Until Pfizer demonstrates it can stabilize earnings through new product success, the stock likely remains vulnerable to further selling pressure in an already nervous healthcare market.<\/p>\n

    \n“The next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and treatment.”\n<\/p><\/blockquote>\n

    \u2014 Pfizer Management<\/b>, Reuters<\/p>\n

    Sources<\/h3>\n
      \n
    • Reuters<\/b> – Pfizer guidance announcement and COVID revenue decline analysis<\/li>\n
    • CNBC<\/b> – Portfolio impact and strategic context on 2026 outlook<\/li>\n
    • Wall Street Journal<\/b> – Earnings per share guidance and investor expectations<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":23,"featured_media":27939,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"schema_org_data":"{\"@context\":\"https:\/\/schema.org\",\"@graph\":[]}","_extracted_celebrities":"","_extracted_movies":"","_extracted_places":"","_extracted_videos":"","_last_enrichment_date":"2025-12-22 11:18:19","footnotes":""},"categories":[391],"tags":[],"class_list":["post-27940","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-finance","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"yoast_head":"\nPFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next\" \/>\n<meta property=\"og:description\" content=\"…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\" \/>\n<meta property=\"og:site_name\" content=\"Red94\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T15:18:05+00:00\" \/>\n<meta name=\"author\" content=\"Patrick Graham\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrick Graham\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\"},\"author\":{\"name\":\"Patrick Graham\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\"},\"headline\":\"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next\",\"datePublished\":\"2025-12-22T15:18:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\"},\"wordCount\":695,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.red94.net\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png\",\"articleSection\":[\"Business & Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\",\"url\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\",\"name\":\"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next\",\"isPartOf\":{\"@id\":\"https:\/\/www.red94.net\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png\",\"datePublished\":\"2025-12-22T15:18:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png\",\"width\":1200,\"height\":678,\"caption\":\"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors nervous\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.red94.net\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entertainment\",\"item\":\"https:\/\/www.red94.net\/news\/entertainment\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.red94.net\/news\/#website\",\"url\":\"https:\/\/www.red94.net\/news\/\",\"name\":\"Red94\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.red94.net\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.red94.net\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.red94.net\/news\/#organization\",\"name\":\"Red94\",\"url\":\"https:\/\/www.red94.net\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png\",\"width\":289,\"height\":90,\"caption\":\"Red94\"},\"image\":{\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9\",\"name\":\"Patrick Graham\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.red94.net\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"contentUrl\":\"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg\",\"caption\":\"Patrick Graham\"},\"description\":\"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.\",\"url\":\"https:\/\/www.red94.net\/news\/author\/patrick-graham\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/","og_locale":"en_US","og_type":"article","og_title":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next","og_description":"…","og_url":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/","og_site_name":"Red94","article_published_time":"2025-12-22T15:18:05+00:00","author":"Patrick Graham","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrick Graham","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#article","isPartOf":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/"},"author":{"name":"Patrick Graham","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9"},"headline":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next","datePublished":"2025-12-22T15:18:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/"},"wordCount":695,"commentCount":0,"publisher":{"@id":"https:\/\/www.red94.net\/news\/#organization"},"image":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage"},"thumbnailUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png","articleSection":["Business & Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/","url":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/","name":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next","isPartOf":{"@id":"https:\/\/www.red94.net\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage"},"image":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage"},"thumbnailUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png","datePublished":"2025-12-22T15:18:05+00:00","breadcrumb":{"@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#primaryimage","url":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/12\/33898-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g.jpg-scaled.png","width":1200,"height":678,"caption":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors nervous"},{"@type":"BreadcrumbList","@id":"https:\/\/www.red94.net\/news\/90244-pfe-stock-tumbles-as-pfizer-slashes-2026-revenue-guidance-amid-covid-headwinds-g\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.red94.net\/news\/"},{"@type":"ListItem","position":2,"name":"Entertainment","item":"https:\/\/www.red94.net\/news\/entertainment\/"},{"@type":"ListItem","position":3,"name":"PFE stock tumbles as Pfizer slashes 2026 revenue guidance amid COVID headwinds, guidance cut has investors wondering what comes next"}]},{"@type":"WebSite","@id":"https:\/\/www.red94.net\/news\/#website","url":"https:\/\/www.red94.net\/news\/","name":"Red94","description":"","publisher":{"@id":"https:\/\/www.red94.net\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.red94.net\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.red94.net\/news\/#organization","name":"Red94","url":"https:\/\/www.red94.net\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/uploads\/2025\/07\/Logo-Red94.png","width":289,"height":90,"caption":"Red94"},"image":{"@id":"https:\/\/www.red94.net\/news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/a87cd0001445db88250833ec7b7ce9a9","name":"Patrick Graham","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.red94.net\/news\/#\/schema\/person\/image\/","url":"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","contentUrl":"https:\/\/www.red94.net\/news\/wp-content\/plugins\/generateperf\/images\/icons\/avatar.svg","caption":"Patrick Graham"},"description":"Patrick Graham is a business and finance journalist translating Wall Street's complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world's biggest moves.","url":"https:\/\/www.red94.net\/news\/author\/patrick-graham\/"}]}},"views":186,"_links":{"self":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts\/27940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/comments?post=27940"}],"version-history":[{"count":0,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/posts\/27940\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/media\/27939"}],"wp:attachment":[{"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/media?parent=27940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/categories?post=27940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.red94.net\/news\/wp-json\/wp\/v2\/tags?post=27940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}